INTRODUCTION
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the t(9;22) chromosomal translocation. This translocation results in the formation of BCR-ABL fusion gene, which is central to the pathogenesis of CML. The BCR-ABL gene exhibits constitutive tyrosine kinase activity, resulting in myeloid proliferation 1 . Imatinib mesylate, a tyrosine kinase inhibitor (TKI), induces durable responses in the majority of CML patients and is currently the standard of care for CML 2, 3 . However, imatinib resistance, usually due to BCR-ABL kinase domain (KD) point mutations, remains a significant problem in the management of CML patients [4] [5] [6] . BCR-ABL mutations have varying effects on the patient's sensitivity to imatinib and other TKIs, and may cause partial or complete resistance depending upon the nature and location of the mutation 5, [7] [8] [9] [10] . The presence of KD mutations has been studied mostly in the advanced phase of CML (accelerated phase and blast crisis), in chronic phase (CP) patients who develop resistance to imatinib, and in Philadelphia-positive (Ph + ) acute lymphoblastic leukemia 5, [10] [11] [12] [13] . BCR-ABL KD mutations can exist in newly diagnosed CP-CML patients and may affect the outcome of imatinib treatment [14] [15] [16] [17] [18] . There are limited data available from imatinib-naive patients in CP-CML regarding the incidence of KD mutations, and the correlation of these mutations with the therapeutic response in unselected patients has not been established 14, [17] [18] . Although KD mutations are infrequently detected in newly diagnosed CP-CML patients 18 , KD mutations were found in a substantial number of patients when CD34 + stem cell were analyzed [19] [20] . Recent studies indicated that a small population of CD34 + CML (stem/progenitor) cells are less responsive to imatinib and other TKIs, and act as a reservoir for the emergence of imatinib-resistant subclones 19, [21] [22] [23] . Thus, the detection of pre-existing mutations (PEMs) in primitive stem/progenitor (CD34 + ) cells may have therapeutic and prognostic implications and is likely to be helpful in optimizing the management of CML patients [19] [20] [21] [22] [23] . Large-scale studies to assess the role of BCR-ABL PEMs in CD34 + cells and their correlation with imatinib therapy in CP-CML are lacking. To address this issue, we analyzed 100 newly diagnosed CP-CML patients for BCR-ABL PEMs in CD34 + CML cells using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) and sequencing, and studied the outcome of these patients after imatinib treatment.
MATERIALS AND METHODS

Patients and definitions
One hundred newly diagnosed CP-CML patients were included in the study. All patients gave informed consent, and the study was approved by the institutional ethics committees of the four participating centers. All patients had newly diagnosed CP-CML at the time samples were taken, and patients with accelerated-phase or blast-crisis CML were excluded. Patients' clinical characteristics are given in Table 1. CP was defined by the presence of less than 15% blasts, less than 20% basophils, and less than 30% blasts and promyelocytes in the peripheral blood and bone marrow (BM) and no extramedullary blastic disease [24] [25] [26] . Complete hematologic response (CHR), complete cytogenetic response (CCR), and a partial cytogenetic response were defined according to previously published response criteria [24] [25] [26] . Briefly, CHR required the normalization of blood counts: leucocytes counts <10,000/mm Resistance patterns were adopted as defined by the LeukemiaNet guidelines 25 . Primary or intrinsic resistance was defined by the failure to achieve CHR by 3 months, any cytogenetic response by 6 months, partial cytogenetic response by 12 months, and complete cytogenetic response by 18 months. Acquired or secondary resistance was defined as the loss of previous hematological, cytogenetic, or molecular responses, sustained CHR that was followed by transformation to the accelerated or blastic phase, Ph . RNA and DNA quality was checked by spectrophotometry, gel electrophoresis, and by the amplification of the ABL gene 14, 30 . As BCR-ABL PEMs are rare among wild-type BCR-ABL and thus cannot be detected by sequencing the whole BCR-ABL KD, we employed a very sensitive ASO-PCR assay for this purpose which has already been optimized and clinically validated using appropriate positive and negative controls elsewhere 31 . This assay can detect 18 of the most clinically relevant and common BCR-ABL mutations 14, [31] [32] . PCR amplifications were performed exactly as reported, Table 2 . HL60 cell line was used as negative control in ASO-PCR reactions. Although we use pre-validated ASO-PCR assays as reproduced those assays using exactly same reaction conditions, reagents and PCR mix formulation, to eliminate the possibility of false-positive results, ASO-PCR products were sequenced using an automated ABI377 sequencer (Applied Biosystems). Sequences were analyzed with Sequence Analysis software V3.3 and Sequence Navigator software V1.0.1 (Applied Biosystems). A mutation was considered present only if it was detected in both strands in two or more independent ASO-PCR amplified products 14, 31, 33 .
Imatinib treatment and response monitoring
All patients were treated with 400 mg of imatinib/day. Clinical studies were performed in collaboration with CML treatment centers. Patients were monitored every 2 weeks for hematological response and every 3 months for cytogenetic and molecular response during imatinib treatment and follow-up. Secondary resistance, as described previously, was also monitored. For imatinib-resistant patients, second-generation TKIs were not available due to financial constraints. However, imatinib-resistant patients were treated with 600-800 mg of imatinib/day, irrespective of presence or absence of PEMs 7 . Patients were monitored regularly every 2 weeks for hematological response and every 12 weeks for cytogenetic and molecular responses after imatinib dose escalation.
Detection of mutations after the manifestation of imatinib resistance
All imatinib-resistant patients, irrespective of their PEM status, were investigated for BCR-ABL mutations using ASO-PCR 14, [31] [32] as well as by DNA sequencing of the RT-PCR-amplified whole BCR-ABL KD. For RT-PCR and DNA sequencing of the BCR-ABL KD, we adopted the protocol described by Branford and Hughes 33 using an automated ABI377 sequencer (Applied Biosystems). HL60 cell line was used as a negative control in PCR and sequencing while KCL22 cell line was used as a positive control. Sequences were analyzed with Sequence Analysis software V3.3 and Sequence Navigator software V1.0.1. To confirm mutation detection by sequencing, the opposite strand of the PCR product was sequenced. Moreover, the whole procedure of RNA extraction, RT-PCR, and sequencing was repeated once. Detection of the mutation was confirmed only if the same mutation was detected in both DNA strands as well as in the repeat analysis 15, 31, 33 .
Statistical Analysis
Various clinical parameters, frequencies of imatinib resistance, and clinical response rates were compared in the two subgroups of patients with and without PEMs by Chi-square test using "Statistical Package for Social Sciences (SPSS)" software, version 17. A p-value of <0.05 was considered significant.
RESULTS
Pre-existing and post-resistance BCR-ABL mutations
BCR-ABL PEMs were detected in 32 out of 100 (32%) patients ( Figure 2 and Table 3 ). We found three mutations, namely T315I, F311L, and M351T, either alone or in combination, as PEMs in this group of CML patients. The frequencies of the M351T, F311L, and T315I mutations were 87.5%, 50%, and 37.5%, respectively, either alone or in combination. Thus, M351T was the most common PEM, whereas T315I was the least common PEM detected ( Figure 2 ). After 12-18 months of imatinib treatment (400 mg/day), all patients with BCR-ABL PEMs exhibited imatinib resistance (32/32, 100%). Upon re-investigation of BCR-ABL mutations in these patients using ASO-PCR and DNA sequencing, all patients had the same PEMs (Figure 1-3) . Regarding the 68 patients without PEMs, imatinib resistance developed in 24 (24/68, 35.3%) patients. BCR-ABL mutations (alone or in combination) were found in 21 of these patients (Table 3 ; Figure 2 ). By DNA sequencing, we were able to detect Y253F mutation in one of the patients as an acquired mutation (not as a PEM). T315I (12/21, 57.1%) and F311L (15/21, 71.5%) were the most common mutations in this group of patients, whereas M351T was detected in 11/21 (52.4%) patients. 
Association of mutations with clinical parameters
Management of resistant patients
Resistant patients were treated with 600-800 mg of imatinib/day irrespective of PEM status.
Patients harboring the T315I mutation (alone or in combination with F311L/M351T) did not exhibit any response, and progressed to accelerated-phase or blast-crises (12/32, 37.5%). In this BCR-ABL PEMs have been reported previously in newly diagnosed CP-CML patients in some studies 14-15, 17, 20 , whereas others failed to detect any mutations in CP-CML patients before treatment initiation despite using sensitive techniques 18 . Most of these studies were limited by a small sample size and CD34 + cell population was not specifically targeted for mutation detection. Ours is the largest study to date on the incidence of naturally occurring BCR-ABL KD mutations using CD34 + cells and their association with imatinib resistance. Although more than 50 BCR-ABL mutations have been reported, we analyzed for the 18 most common mutations as 1) they cover more than 90% of the mutations responsible for imatinib resistance and not all the mutations are clinically relevant 18, 20 , 2) these 18 mutations can be detected by ASO-PCR which is the most sensitive technique to detect low copy number mutations like pre-existing BCR-ABL mutations, 3) we did not have facilities like denaturing HPLC to detect each and every mutation. . Furthermore, it is also known that patients with advanced CP-CML are more likely to exhibit various KD mutations and primary resistance 5 . Many patients in our area present late due to a lack of education, poor knowledge, and the use of traditional remedies before seeking medical advice. Therefore, we cannot rule out the possibility that our patient population may be skewed toward a higher-risk group of CP-CML patients 19 . This could explain the higher mutation detection rate in some of these patients. It is tempting to speculate that this patient population may have a different disease biology, but we have no convincing evidence to support this notion . All of our resistant patients were treated with imatinib dose escalation to 600-800 mg daily irrespective of their PEM status. We did not have an opportunity to treat imatinib-resistant patients with second-line TKIs because these agents were not obtainable due to the high cost and lack of funding (only imatinib is supplied free of cost to these patients by a non-governmental organization). Twelve patients with T315I PEM (alone or in combination with F311L and/or M351T) did not respond to imatinib dose escalation, and they progressed to accelerated-phase or blast-crisis. In this group of the patients with F311L and/or M351T mutations, 16 of 20 patients exhibited complete hematological, cytogenetic, and molecular responses to dose escalation, whereas the other four patients exhibited partial cytogenetic responses. Fifteen CML patients without PEMs harboring T315I mutation (alone or in combination with F311L, M351T, and/or T253L mutations) did not respond to imatinib dose escalation, as expected, and progressed, whereas 7 out of 9 patients harboring F311L and/or M351T mutations responded to dose escalation, achieving complete hematological and cytogenetic responses. Overall, 31 CML patients remained resistant to imatinib even after dose escalation.
Currently, screening for BCR-ABL mutations is not recommended in newly diagnosed CP-CML patients 25 because the frequency of mutations in these patients was found to be low in previous studies, these mutations may not necessarily correlate with response, and the screening costs are prohibitive 18, 25, 36, 39 . According to the European LeukemiaNet guidelines for CML management, mutation analysis of CP-CML patients treated with imatinib should be performed when there is evidence of inadequate response or loss of response 25 . Our study revealed that using sensitive techniques, BCR-ABL KD mutations may be found in a substantial number of patients and correlate with the response to imatinib therapy. After the recent approval of two second-line TKIs-dasatinib and nilotinib-by the FDA for the frontline treatment of CML, knowledge about the presence and type of mutations may facilitate timely decision making regarding the choice of therapy at the time of diagnosis. Patients with mutations known to confer resistance to standard or high doses of imatinib can benefit from an upfront treatment with a second-line TKI. For patients with mutations such as T315I, which is known to confer resistance to all currently approved TKIs, one of the newer agents such as ponatinib (AP24534) which is effective against this mutation [40] [41] , or allogeneic transplantation must be considered.
We acknowledge the fact that there is high incidence of imatinib resistance in our study patients.
Patients with CML vary in their response to treatment and although the basis for this variation is not known, it has been attributed to the biologic heterogeneity of the disease. Some of the factors implicated in poor response to CML therapy include low level of expression of molecular 
